EGFR as a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies
The DOI matches its Crossref record.
Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is among the most lethal solid tumors with grim prognosis. This dismal outcome can partially be explained by the resistance to currently available chemotherapy regimens or the failure of most anticancer agents, which prompted the development of new and effective therapeutic-approaches, such as inhibitors of the epidermal growth factor receptor (EGFR). Some of these EGFR inhibitors (e.g., erlotinib) are approved for lungcancer, however available data are inconclusive for treatment of pancreatic cancer patients with EGFR-targeted-therapies. Here we describe the critical role of EGFR pathway in pancreatic-cancer, strategies to enhance the effectiveness of EGFRinhibitors as well as the preclinical/clinical studies with particular emphasis on recent findings with monoclonal antibodies and tyrosine-inhibitors. Several combinations of EGFR inhibitors with other agents illustrate inhibition of tumor-induced angiogenesis and cell growth. Moreover, combination of erlotinib with gemcitabine showed statistically significance in overall-survival, compared to gemcitabine-alone. However high cost, little survival gain and increased risk of toxicities have limited its efficacy. Considering the multiple genetic mutations and the crosstalk of signaling pathways, (1) development of multiple targeted-therapies; (2) identification of predictive-biomarkers; and (3) those patients who are most likely benefit from therapy, could provide valuable direction for the clinical development of EGFR inhibitors. Moreover further preclinical/clinical studies are warranted to identify determinants of the activity of EGFR-inhibitors and mechanisms leading to resistance to EGFR inhibitors, through the analysis of genetic and environmental alterations affecting EGFR and parallel pro-cancer pathways. These studies will be critical to improve the efficacy and selectivity of current anticancer strategies targeting EGFR in pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Emami Nejad, A., Najafgholian, S., Rostami, A., Sistani, A., Shojaeifar, S., Esparvarinha, M., Nedaeinia, R., Haghjooy Javanmard, S., Taherian, M., Ahmadlou, M., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01719-5 · Cited by 693
Self-citationDesign of liposomal formulations for cell targeting
Nogueira, E., Gomes, A. C., Preto, A., & Cavaco-Paulo, A. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.09.034 · Cited by 173
Xu, J., Xiong, G., Cao, Z., Huang, H., Wang, T., You, L., Zhou, L., Zheng, L., Hu, Y., Zhang, T., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0406-z · Cited by 53
“Epidermal growth factor receptor (EGFR) has also been shown to play key roles in multiple malignant processes involved in cellular proliferation, apoptosis prevention, drug resistance, cancer stem cell marker expression and metastasis in pancreatic cancer [10].”
SOX9 is a critical regulator of TSPAN8-mediated metastasis in pancreatic cancer
Li, J., Chen, X., Zhu, L., Lao, Z., Zhou, T., Zang, L., Ge, W., Jiang, M., Xu, J., Cao, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01864-9 · Cited by 45
Metadata
- Authors
- Nedaeinia, R., Avan, A., Manian, M., Salehi, R., & Ghayour-Mobarhan, M.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-12
- Volume
- 15
- Issue
- 14
- Pages
- 1293-1301
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2145063333
- Cited by
- 62
- References
- 0
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EGFR as a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies. https://app.cochat.ai/papers/10.2174/1389450115666141125123003
- The paper
- Nedaeinia, R., Avan, A., Manian, M., Salehi, R., & Ghayour-Mobarhan, M. (2014). EGFR as a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies. Current Drug Targets. https://doi.org/10.2174/1389450115666141125123003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.